ATE122727T1 - Zubereitungen und verfahren für klone, die, mit mehrfacharzneimittelresistenz assoziierte, dna- sequenzen in menschlichen zellen enthalten. - Google Patents

Zubereitungen und verfahren für klone, die, mit mehrfacharzneimittelresistenz assoziierte, dna- sequenzen in menschlichen zellen enthalten.

Info

Publication number
ATE122727T1
ATE122727T1 AT87903043T AT87903043T ATE122727T1 AT E122727 T1 ATE122727 T1 AT E122727T1 AT 87903043 T AT87903043 T AT 87903043T AT 87903043 T AT87903043 T AT 87903043T AT E122727 T1 ATE122727 T1 AT E122727T1
Authority
AT
Austria
Prior art keywords
preparations
methods
dna sequences
drug resistance
human cells
Prior art date
Application number
AT87903043T
Other languages
English (en)
Inventor
Igor B Roninson
Ira H Pastan
Michael M Gottesman
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27126587&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE122727(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Illinois filed Critical Univ Illinois
Application granted granted Critical
Publication of ATE122727T1 publication Critical patent/ATE122727T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT87903043T 1986-03-28 1987-03-26 Zubereitungen und verfahren für klone, die, mit mehrfacharzneimittelresistenz assoziierte, dna- sequenzen in menschlichen zellen enthalten. ATE122727T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84561086A 1986-03-28 1986-03-28
US89257586A 1986-08-01 1986-08-01

Publications (1)

Publication Number Publication Date
ATE122727T1 true ATE122727T1 (de) 1995-06-15

Family

ID=27126587

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87903043T ATE122727T1 (de) 1986-03-28 1987-03-26 Zubereitungen und verfahren für klone, die, mit mehrfacharzneimittelresistenz assoziierte, dna- sequenzen in menschlichen zellen enthalten.

Country Status (7)

Country Link
EP (1) EP0274482B2 (de)
JP (1) JP2634833B2 (de)
AT (1) ATE122727T1 (de)
AU (1) AU614489B2 (de)
CA (1) CA1341013C (de)
DE (1) DE3751307T2 (de)
WO (1) WO1987005943A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837306A (en) * 1985-02-25 1989-06-06 The Ontario Cancer Institute Method for selecting hybridomas producing antibodies specific to the P-glycoprotein cell suface antigen and a cDNA clone encoding the C-terminal portion of the antigen
US5085983A (en) * 1988-08-19 1992-02-04 City Of Hope Detection of human tumor progression and drug resistance
US5399483A (en) * 1989-03-30 1995-03-21 Suntory Limited Expression of MDR-related gene in yeast cell
WO1992001811A1 (en) * 1990-07-25 1992-02-06 Imperial Cancer Research Technology Limited Assay for ctp-synthetase mutations which cause multidrug resistance
DE69128253T2 (de) * 1990-10-29 1998-06-18 Chiron Corp Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
US6130059A (en) * 1992-03-02 2000-10-10 Covacci; Antonello Helicobacter pylori proteins useful for vaccines and diagnostics
US7141244B1 (en) 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
EP0967279B1 (de) 1992-03-02 2008-01-02 Novartis Vaccines and Diagnostics S.r.l. Helicobacter pylori Cytotoxin verwendbar in Impfstoffe und Diagnostik
US5489519A (en) * 1992-10-27 1996-02-06 Queen's University At Kingston Multidrug resistance protein
AU5420494A (en) * 1992-11-02 1994-05-24 Yves Claude Nicolau Method of reducing multidrug resistance in cells and tissues
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
EP0909323B1 (de) 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Bakterioferritin aus helicobacter pylori
CA2386029A1 (en) 1999-09-28 2001-04-05 Gentest Corporation P-glycoproteins from macaca fascicularis and uses thereof
EP1421101A4 (de) 2001-03-19 2005-01-19 Gentest Corp P-glycoproteine und deren verwendungen
WO2003025174A2 (en) * 2001-09-06 2003-03-27 Bayer Healthcare Ag Regulation of human mrp1-like protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0174810B1 (de) * 1984-09-10 1993-07-21 HSC Research Development Corporation Vielfache Drogen-Resistenz in Säugetierzellinien und Isolierung der determinanten Glykoprotein-DNS
DE3580726D1 (de) * 1984-09-13 1991-01-10 Globe Products Inc Dynamoelektrisches flachspulbauteil, dessen ausgangsform, verfahren und geraet zur herstellung.

Also Published As

Publication number Publication date
EP0274482A4 (de) 1989-05-23
AU7286187A (en) 1987-10-20
AU614489B2 (en) 1991-09-05
JP2634833B2 (ja) 1997-07-30
JPH01500480A (ja) 1989-02-23
EP0274482A1 (de) 1988-07-20
CA1341013C (en) 2000-06-06
WO1987005943A1 (en) 1987-10-08
EP0274482B2 (de) 2003-03-12
DE3751307T2 (de) 1995-09-21
DE3751307D1 (de) 1995-06-22
EP0274482B1 (de) 1995-05-17

Similar Documents

Publication Publication Date Title
ATE122727T1 (de) Zubereitungen und verfahren für klone, die, mit mehrfacharzneimittelresistenz assoziierte, dna- sequenzen in menschlichen zellen enthalten.
Erickson et al. Identification of breakpoints in t (8; 21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt
Kruse et al. Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria
Schutte et al. A preliminary gene map for the Van der Woude syndrome critical region derived from 900 kb of genomic sequence at 1q32–q41
Haas-Rochholz et al. Additional primer sets for an amelogenin gene PCR-based DNA-sex test
Bliss et al. Gene expression profiling of avian macrophage activation
Minervini et al. Mutational analysis in BCR-ABL1 positive leukemia by deep sequencing based on nanopore MinION technology
Lifshitz et al. Bcr genes and transcripts
ATE454468T1 (de) Nachweis der instabilität von mikrosatelliten und verwendung davon bei der tumordiagnose
CA2760518C (en) Epigenetic marker for the identification of natural killer cells
ATE455187T1 (de) Dna-arrays zur messung der empfindlichkeit gegenüber einem antikrebsmittel
CN106754903A (zh) 一种用于人类线粒体的全基因组扩增的引物对及方法
Marcelle et al. Analysis of BCR‐ABL mRNA in chronic myelogenous leukemia patients and identification of a new BCR‐related sequence in human DNA
Wilson et al. Human globin messenger RNA: importance of cloning for structural analysis
KR101566472B1 (ko) 뽕나무 동정방법
Zaccaria et al. The type of BCR/ABL junction does not predict the survival of patients with Ph1‐positive chronic myeloid leukaemia
CN106834450A (zh) 一种用于t细胞白血病微小残留病检测的方法
CN104561015B (zh) Myl4基因突变体及其应用
Hu et al. Generation of a complete set of human telomeric band painting probes by chromosome microdissection
DE69833104D1 (de) Glaukom diagnose und behandlung
ATE150797T1 (de) Mittel zur komplexen diagnostik der genexpression und verfahren zur anwendung für die medizinische diagnostik und die genisolierung
ATE207536T1 (de) Nukleotid sequenzen und daraus abgleitete aminosäuresequenzen vom tumorgen int 6
EP2768975B1 (de) Epigenetischer marker zur identifikation von il17-positiven t-zellen in komplexen proben
Chaitanya Diagnostics and Gene Therapy for Human Genetic Disorders
Tilanus et al. Molecular analysis of HLA: haplotype-specific DNA hybridization patterns using class II cDNA probes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification

Ref document number: 0274482

Country of ref document: EP

EELA Cancelled due to lapse of time